Pegfilgrastim works by binding to specific receptors on the surface of hematopoietic cells in the bone marrow. This interaction stimulates the production, differentiation, and release of neutrophils into the bloodstream. The pegylation process (attachment of a polyethylene glycol molecule) extends the drug's half-life, allowing for less frequent dosing compared to its predecessor, filgrastim.